Background The purpose of this study was to investigate the predictive value of tumor
metabolic parameters in combination with secondary lymphoid metabolic parameters on …

Purpose This research aims to investigate the predictive capacity of PET/CT quantitative
parameters combined with haematological parameters in advanced lung cancer patients …

Simple Summary Lung cancer is the leading cause of cancer-related death worldwide.
Nonsmall cell lung cancer (NSCLC) accounts for 80–85% of all cases. Immune checkpoint …

Purpose We aimed to evaluate if imaging biomarkers on FDG PET are associated with
clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with …

Purpose This prospective study evaluated whether peripheral blood biomarkers and
metabolic parameters on F-18 fludeoxyglucose positron emission tomography/computed …

81 Objectives: The aim of this study was to identify whether metabolic parameters evaluated
by 18F-FDG PET/CT and peripheral blood biomarkers were associated with clinical …

Simple Summary The advent of immune-checkpoint inhibitors (ICIs) has significantly
changed the management of patients with non-small cell lung cancer (NSCLC). Although …

Objectives: We aimed to assess the predictive value of the total metabolic tumor burden prior
to treatment in patients with advanced non-small-cell lung cancer (NSCLC) receiving …

Simple Summary Positron-emission tomography/computed tomography (PET/CT) is used for
staging of non-small cell lung cancer (NSCLC) and can help to estimate prognosis in …

Background: A significant proportion of patients with non-small-cell lung cancer (NSCLC) do
not respond to immune checkpoint inhibitors (ICIs). Since metabolic reprogramming with …